These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 21480391

  • 1. Overcoming resistance to fulvestrant (ICI182,780) by downregulating the c-ABL proto-oncogene in breast cancer.
    Zhao H, Lo YH, Yu L, Wang SC.
    Mol Carcinog; 2011 May; 50(5):383-9. PubMed ID: 21480391
    [Abstract] [Full Text] [Related]

  • 2. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
    Ribas R, Pancholi S, Guest SK, Marangoni E, Gao Q, Thuleau A, Simigdala N, Polanska UM, Campbell H, Rani A, Liccardi G, Johnston S, Davies BR, Dowsett M, Martin LA.
    Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
    [Abstract] [Full Text] [Related]

  • 3. Combined inhibition of EGFR and c-ABL suppresses the growth of fulvestrant-resistant breast cancer cells through miR-375-autophagy axis.
    Liu L, Shen W, Zhu Z, Lin J, Fang Q, Ruan Y, Zhao H.
    Biochem Biophys Res Commun; 2018 Apr 06; 498(3):559-565. PubMed ID: 29522716
    [Abstract] [Full Text] [Related]

  • 4. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P, Chatterjee S, Bhat V, Su A, Jin H, Lee-Wing V, Liu Q, Hu P, Murphy LC, Raouf A.
    Cell Physiol Biochem; 2018 Apr 06; 51(4):1518-1532. PubMed ID: 30497079
    [Abstract] [Full Text] [Related]

  • 5. Silencing MED1 sensitizes breast cancer cells to pure anti-estrogen fulvestrant in vitro and in vivo.
    Zhang L, Cui J, Leonard M, Nephew K, Li Y, Zhang X.
    PLoS One; 2013 Apr 06; 8(7):e70641. PubMed ID: 23936234
    [Abstract] [Full Text] [Related]

  • 6. Binding of anterior gradient 2 and estrogen receptor-α: Dual critical roles in enhancing fulvestrant resistance and IGF-1-induced tumorigenesis of breast cancer.
    Li Z, Zhu Q, Chen H, Hu L, Negi H, Zheng Y, Ahmed Y, Wu Z, Li D.
    Cancer Lett; 2016 Jul 10; 377(1):32-43. PubMed ID: 27063095
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of c-Abl kinase activity renders cancer cells highly sensitive to mitoxantrone.
    Alpay K, Farshchian M, Tuomela J, Sandholm J, Aittokallio K, Siljamäki E, Kallio M, Kähäri VM, Hietanen S.
    PLoS One; 2014 Jul 10; 9(8):e105526. PubMed ID: 25148385
    [Abstract] [Full Text] [Related]

  • 8. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.
    Mishra AK, Abrahamsson A, Dabrosin C.
    Oncotarget; 2016 Aug 30; 7(35):56876-56888. PubMed ID: 27486755
    [Abstract] [Full Text] [Related]

  • 9. Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells.
    Song RX, Chen Y, Zhang Z, Bao Y, Yue W, Wang JP, Fan P, Santen RJ.
    J Steroid Biochem Mol Biol; 2010 Feb 28; 118(4-5):219-30. PubMed ID: 19815064
    [Abstract] [Full Text] [Related]

  • 10. Doxorubicin induces atypical NF-κB activation through c-Abl kinase activity in breast cancer cells.
    Esparza-López J, Medina-Franco H, Escobar-Arriaga E, León-Rodríguez E, Zentella-Dehesa A, Ibarra-Sánchez MJ.
    J Cancer Res Clin Oncol; 2013 Oct 28; 139(10):1625-35. PubMed ID: 23892407
    [Abstract] [Full Text] [Related]

  • 11. Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase.
    Yeh WL, Shioda K, Coser KR, Rivizzigno D, McSweeney KR, Shioda T.
    PLoS One; 2013 Oct 28; 8(4):e60889. PubMed ID: 23593342
    [Abstract] [Full Text] [Related]

  • 12. Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1.
    Sims JT, Ganguly SS, Bennett H, Friend JW, Tepe J, Plattner R.
    PLoS One; 2013 Oct 28; 8(1):e55509. PubMed ID: 23383209
    [Abstract] [Full Text] [Related]

  • 13. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
    Sui M, Jiang D, Hinsch C, Fan W.
    Breast Cancer Res Treat; 2010 Jun 28; 121(2):335-45. PubMed ID: 19626437
    [Abstract] [Full Text] [Related]

  • 14. p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines.
    Fernandez-Cuesta L, Anaganti S, Hainaut P, Olivier M.
    Int J Cancer; 2011 Apr 15; 128(8):1813-21. PubMed ID: 20549698
    [Abstract] [Full Text] [Related]

  • 15. High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer.
    Alves CL, Elias D, Lyng M, Bak M, Kirkegaard T, Lykkesfeldt AE, Ditzel HJ.
    Clin Cancer Res; 2016 Nov 15; 22(22):5514-5526. PubMed ID: 27252418
    [Abstract] [Full Text] [Related]

  • 16. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL, Yde CW, Laenkholm AV, Rasmussen BB, Duun-Henriksen AK, Bak M, Lykkesfeldt AE, Kirkegaard T.
    BMC Cancer; 2015 Apr 08; 15():239. PubMed ID: 25885472
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016).
    Lo YH, Ho PC, Zhao H, Wang SC.
    Anticancer Res; 2011 Mar 08; 31(3):789-95. PubMed ID: 21498698
    [Abstract] [Full Text] [Related]

  • 18. Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.
    Weigel MT, Ghazoui Z, Dunbier A, Pancholi S, Dowsett M, Martin LA.
    Breast Cancer Res; 2012 May 18; 14(3):R78. PubMed ID: 22608253
    [Abstract] [Full Text] [Related]

  • 19. Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells.
    Liu H, Cheng D, Weichel AK, Osipo C, Wing LK, Chen B, Louis TE, Jordan VC.
    Int J Oncol; 2006 Nov 18; 29(5):1237-46. PubMed ID: 17016657
    [Abstract] [Full Text] [Related]

  • 20. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
    Dai Y, Rahmani M, Corey SJ, Dent P, Grant S.
    J Biol Chem; 2004 Aug 13; 279(33):34227-39. PubMed ID: 15175350
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.